Could extra doses of a hormone boost IVF success for high responders?
NCT ID NCT07569315
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares giving three doses of a GnRH agonist (triptorelin) versus the usual single dose to trigger ovulation in women who produce many eggs during IVF. The goal is to see if multiple doses lead to more mature eggs and higher pregnancy rates. The trial plans to enroll 190 women classified as hyper-responders.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Triptorelin (GnRH agonist)
What this could lead to
If successful, this could improve the number of mature eggs retrieved during IVF for women who over-respond to stimulation, potentially increasing pregnancy chances.
What could go wrong
This is a small Phase 2 trial, so results may not apply broadly. The intervention is a variation of an existing drug, so the benefit over standard care may be modest or absent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFERTILITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bedaya Hospital
Giza, Egypt
Contact
Contact Email: •••••@•••••